Drug Profile
Research programme: neuropeptide Y antagonists - Alanex
Alternative Names: Neuropeptide Y antagonistsLatest Information Update: 23 Aug 2006
Price :
$50
*
At a glance
- Originator Alanex Corporation
- Class
- Mechanism of Action Neuropeptide Y receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders; Obesity
Most Recent Events
- 23 Aug 2006 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 23 Aug 2006 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 05 Oct 2001 No-Development-Reported for Cardiovascular disorders in USA (Unknown route)